[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hi Tech Pharmacal Co. Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

March 2024 | 50 pages | ID: HF81E1094BCBEN
BAC Reports

US$ 499.00

Email Delivery - PDF (on default)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Hi Tech Pharmacal Co. Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Hi Tech Pharmacal Co. Inc. and its competitors. This provides our Clients with a clear understanding of Hi Tech Pharmacal Co. Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Hi Tech Pharmacal Co. Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Hi Tech Pharmacal Co. Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Hi Tech Pharmacal Co. Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Hi Tech Pharmacal Co. Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Hi Tech Pharmacal Co. Inc. business.

About Hi Tech Pharmacal Co. Inc.

Hi-Tech Pharmacal Co., Inc. operates as a specialty manufacturer and marketer of prescription, over-the-counter, and nutritional products. The company produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, and other conditions.

Products

The company develops, manufactures, and markets products in three categories – Generics, Prescription Brands, and Over the Counter (OTC) Brands.

Generic Products

The company’s generic products are primarily prescription items and include oral solutions and suspensions, topical creams, and ointments, as well as nasal sprays. It also manufactures products in its sterile facility capable of producing liquid ophthalmic, otic, and inhalation products. Additionally, its Midlothian Laboratories division sources and markets generic prescription products, which primarily include prescription vitamins. The generic product category also includes an amount of contract manufacturing sales for both the prescription and OTC markets.

The company’s primary generic products include Dorzolamide with Timolol and Dorzolamide (the generic equivalents of Cosopt and Trusopt from Merck); Fluticasone propionate (the generic equivalent of Flonase from GlaxoSmithKline); Acetic Acid with Hydrocortisone (the generic equivalent of Vosol HC from ECR); Sulfamethoxazole with Trimethoprim (the generic equivalent of Bactrim from Roche); and Acyclovir oral suspension (the generic equivalent of Zovirax from GlaxoSmithKline). It has 43 prescription products approved for marketing by the Food and Drug Administration (FDA) and 1 product with tentative approval.

ECR Pharmaceuticals

The company, through its subsidiary, E. Claiborne Robins Company, Inc. doing business as ECR Pharmaceuticals (ECR Pharmaceuticals or ECR), engages in the development and distribution of branded prescription pharmaceuticals. ECR’s products treat various disease states, including cough and cold symptoms, allergies, poison ivy and contact dermatitis, and pain relief. It has purchased the rights to Zolpimist, Zolpidem tartrate oral spray, for the treatment of insomnia.

ECR’s primary products include Lodrane 24/Lodrane 24 D, an extended release antihistamine/ antihistamine with decongestant capsule; DexPak TaperPak, an oral corticosteroid tablet available in 13 day, 10 day, and 6 day tapered packages; Bupap, an analgesic tablet; Vosol HC, a treatment for swimmer’s ear; and Tropazone, a treatment for dermatitis.

Health Care Products Division

The Health Care Products Division (HCP) markets a line of OTC branded products that include over-the-counter medications, nutritional products, cosmetics, and medical devices, primarily for people with diabetes. HCP also has various lines that fall outside the diabetes area in pain management and allergy products.

The company markets a line of OTC branded products primarily for people with diabetes, including Diabetic Tussin cough products; DiabetiDerm dermatological and footcare products; Multi-betic multi-vitamins; Mag-Ox magnesium supplement; Choice DM; and DiabetiSweet. The division also sells the Zostrix brand of capsaicin products for pain management of conditions including arthritis and diabetic foot pain. In addition, HCP markets Nasal Ease homeopathic allergy reliever.

Customers

The company markets its products to chain drug stores, drug wholesalers, managed care purchasing organizations, certain federal government agencies, generic distributors, mass merchandisers, and mail-order pharmacies. Its major customers include McKesson Corporation, Cardinal Health, Inc., AmeriSourceBergen Corporation, CVS, Walgreens, and Wal-Mart.

Suppliers

The company’s primary supplier is Ragactives S.L.U.

Competition

The company's competitors include Wockhardt, Qualitest, Actavis, Falcon, Bausch and Lomb, and Apotex.

History

Hi-Tech Pharmacal Co., Inc. was founded in 1982.


The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

RESEARCH METHODOLOGY

DISCLAIMER

1. HI TECH PHARMACAL CO. INC. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. HI TECH PHARMACAL CO. INC. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. HI TECH PHARMACAL CO. INC. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. HI TECH PHARMACAL CO. INC. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. HI TECH PHARMACAL CO. INC. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Hi Tech Pharmacal Co. Inc. Direct Competitors
5.2. Comparison of Hi Tech Pharmacal Co. Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Hi Tech Pharmacal Co. Inc. and Direct Competitors Stock Charts
5.4. Hi Tech Pharmacal Co. Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Hi Tech Pharmacal Co. Inc. Industry Position Analysis

6. HI TECH PHARMACAL CO. INC. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. HI TECH PHARMACAL CO. INC. EXPERTS REVIEW1

7.1. Experts Consensus
7.2. Experts Revisions

8. HI TECH PHARMACAL CO. INC. ENHANCED SWOT ANALYSIS2

9. UNITED STATES PESTEL ANALYSIS2

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. HI TECH PHARMACAL CO. INC. IFE, EFE, IE MATRICES2

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. HI TECH PHARMACAL CO. INC. PORTER FIVE FORCES ANALYSIS2

12. HI TECH PHARMACAL CO. INC. VRIO ANALYSIS2


APPENDIX: RATIO DEFINITIONS


LIST OF FIGURES

Hi Tech Pharmacal Co. Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Hi Tech Pharmacal Co. Inc. 1-year Stock Charts
Hi Tech Pharmacal Co. Inc. 5-year Stock Charts
Hi Tech Pharmacal Co. Inc. vs. Main Indexes 1-year Stock Chart
Hi Tech Pharmacal Co. Inc. vs. Direct Competitors 1-year Stock Charts
Hi Tech Pharmacal Co. Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

LIST OF TABLES

Hi Tech Pharmacal Co. Inc. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Hi Tech Pharmacal Co. Inc. Key Executives
Hi Tech Pharmacal Co. Inc. Major Shareholders
Hi Tech Pharmacal Co. Inc. History
Hi Tech Pharmacal Co. Inc. Products
Revenues by Segment
Revenues by Region
Hi Tech Pharmacal Co. Inc. Offices and Representations
Hi Tech Pharmacal Co. Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Hi Tech Pharmacal Co. Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Hi Tech Pharmacal Co. Inc. Capital Market Snapshot
Hi Tech Pharmacal Co. Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Hi Tech Pharmacal Co. Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Hi Tech Pharmacal Co. Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.


Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.


PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.


Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?


More Publications